These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. Kabir S; Cidado J; Andersen C; Dick C; Lin PC; Mitros T; Ma H; Baik SH; Belmonte MA; Drew L; Corn JE Elife; 2019 Jul; 8():. PubMed ID: 31294695 [TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444 [No Abstract] [Full Text] [Related]
10. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799 [TBL] [Abstract][Full Text] [Related]
11. Novel regulatory roles of Mff and Drp1 in E3 ubiquitin ligase MARCH5-dependent degradation of MiD49 and Mcl1 and control of mitochondrial dynamics. Cherok E; Xu S; Li S; Das S; Meltzer WA; Zalzman M; Wang C; Karbowski M Mol Biol Cell; 2017 Feb; 28(3):396-410. PubMed ID: 27932492 [TBL] [Abstract][Full Text] [Related]
12. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477. Mallick DJ; Soderquist RS; Bates D; Eastman A Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196 [TBL] [Abstract][Full Text] [Related]
13. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. Chiou JT; Lee YC; Wang LJ; Chang LS Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756 [TBL] [Abstract][Full Text] [Related]
14. ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. Chiou JT; Chang LS Biochem Pharmacol; 2024 Jun; 224():116242. PubMed ID: 38679209 [TBL] [Abstract][Full Text] [Related]
15. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434 [TBL] [Abstract][Full Text] [Related]
18. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics. S Soderquist R; Eastman A Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975 [TBL] [Abstract][Full Text] [Related]
19. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092 [TBL] [Abstract][Full Text] [Related]
20. The carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1. Pang X; Zhang J; Lopez H; Wang Y; Li W; O'Neill KL; Evans JJ; George NM; Long J; Chen Y; Luo X J Biol Chem; 2014 Jun; 289(25):17802-11. PubMed ID: 24811167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]